Fertilis

Fertilis is an Australian medtech company focused on advancing micro-medical technology to enhance in vitro fertilization (IVF) procedures. Founded in 2019 by Professor Jeremy Thompson, Professor David Gardner, and Marty Gauvin, the company aims to improve embryo quality and quantity while increasing procedural efficiency. The flagship product, the microICSI device, is designed to enhance the intracytoplasmic sperm injection (ICSI) process. This micro-fabricated tool stabilizes oocytes during injection, improving precision and reducing the need for manual adjustments. Research indicates that microICSI can significantly boost blastocyst development rates, showing promise for human IVF treatments. Headquartered in Adelaide, Fertilis targets fertility clinics and individuals facing infertility, a condition that affects about 1 in 6 people worldwide. The company's technology is built on over 20 years of research, developed in collaboration with the Centre for Nanoscale Biophotonics and the University of Melbourne.

• Employees 15
• Founded 2020
• Total Funding $1980000